Literature DB >> 10596910

Expression of angiogenic and immunosuppressive factors by uveal melanoma cell lines.

S A Ijland1, M J Jager, B M Heijdra, J R Westphal, R Peek.   

Abstract

Dissemination of uveal melanomas is almost exclusively haematogenous, making angiogenesis of the tumour a prerequisite for the formation of metastases. Uveal melanomas must employ strategies to evade the immune system in order to escape immune surveillance. We therefore determined the expression of the following angiogenic and immunosuppressive factors in seven human uveal melanoma cell lines using reverse transcriptase-polymerase chain reaction (RT-PCR): secreted interleukin-1 receptor antagonist (sIL-1ra), interleukin (IL)-6, IL-8, IL-10, transforming growth factor (TGF)-alpha, TGFbeta, vascular endothelial growth factor (VEGF), platelet derived growth factor (PDGF), basic fibroblast growth factor (bFGF), angiopoietin-1 and angiopoietin-2. In addition, the secretion of sIL-1ra, IL-6, IL-8, IL-10, TGFbeta and VEGF was assayed by enzyme linked immunosorbent assay (ELISA). The potential of uveal melanoma cell lines to convert plasminogen to angiostatin was tested in an in vitro assay. All the factors except angiopoietin-1 were determined in one or more cell lines using RT-PCR, although these results were not necessarily confirmed by ELISA. Expression of VEGF and angiopoietin-2 was found in all seven cell lines. Production of angiostatin was observed in one cell line. All seven cell lines examined expressed angiogenic factors and most cell lines expressed immunosuppressive factors. The expression of VEGF and angiopoietin-2 in combination with a lack of angiopoietin-1 expression suggest high vascular remodelling capacity and could be of great relevance for the metastatic potential of uveal melanoma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10596910     DOI: 10.1097/00008390-199910000-00003

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  19 in total

Review 1.  Angiogenesis and melanoma.

Authors:  J P Dutcher
Journal:  Curr Oncol Rep       Date:  2001-07       Impact factor: 5.075

2.  A pilot study of bevacizumab and interferon-α2b in ocular melanoma.

Authors:  Kristan D Guenterberg; Valerie P Grignol; Kiran V Relekar; Kimberly A Varker; Helen X Chen; Kari L Kendra; Thomas E Olencki; William E Carson
Journal:  Am J Clin Oncol       Date:  2011-02       Impact factor: 2.339

3.  Effects of interleukin-1 receptor antagonist on tumor stroma in experimental uveal melanoma.

Authors:  Pierre L Triozzi; Wayne Aldrich; Arun Singh
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-07-25       Impact factor: 4.799

Review 4.  Angiogenesis, thrombospondin, and ductal carcinoma in situ of the breast.

Authors:  A Rice; C M Quinn
Journal:  J Clin Pathol       Date:  2002-08       Impact factor: 3.411

Review 5.  Immunotherapy for uveal melanoma.

Authors:  Dae Won Kim; Jaime Anderson; Sapna P Patel
Journal:  Melanoma Manag       Date:  2016-05-19

6.  Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouring uveal melanoma: identification of a potential therapeutic window.

Authors:  S R Boyd; D Tan; C Bunce; A Gittos; M H Neale; J L Hungerford; S Charnock-Jones; I A Cree
Journal:  Br J Ophthalmol       Date:  2002-04       Impact factor: 4.638

7.  Uveal melanomas express vascular endothelial growth factor and basic fibroblast growth factor and support endothelial cell growth.

Authors:  S R Boyd; D S W Tan; L de Souza; M H Neale; N E Myatt; R A Alexander; M Robb; J L Hungerford; I A Cree
Journal:  Br J Ophthalmol       Date:  2002-04       Impact factor: 4.638

8.  Expression of angiostatin cDNA in human hepatocellular carcinoma cell line SMMC-7721 and its effect on implanted carcinoma in nude mice.

Authors:  Kai-Shan Tao; Ke-Feng Dou; Xing-An Wu
Journal:  World J Gastroenterol       Date:  2004-05-15       Impact factor: 5.742

9.  Presence and phenotype of dendritic cells in uveal melanoma.

Authors:  Marta E Polak; Nicola J Borthwick; Penny Johnson; John L Hungerford; Bernie Higgins; Silvana Di Palma; Martine J Jager; Ian A Cree
Journal:  Br J Ophthalmol       Date:  2007-03-08       Impact factor: 4.638

10.  Early SD-OCT diagnosis followed by prompt treatment of radiation maculopathy using intravitreal bevacizumab maintains functional visual acuity.

Authors:  Nisha V Shah; Samuel K Houston; Arnold M Markoe; William Feuer; Timothy G Murray
Journal:  Clin Ophthalmol       Date:  2012-10-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.